Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India

Hepatology Research

Volumn 41, Issue 1, 2011, Pages 71-78

  Srivastava, Anshika ^a   Srivastava, Anvesha ^a   Srivastava, Neena ^c   Choudhuri, Gourdas ^b   Mittal, Balraj ^a  

^a Departments of Genetics   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Gallstone; PCR RFLP; Polymorphism; SLCO1B1; Transporters

Indexed keywords

BILE SALT; CHOLESTEROL; GENOMIC DNA; ORGANIC ANION TRANSPORTER 2;

ADULT; ARTICLE; CHOLESTEROL STONE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FALSE POSITIVE RESULT; FEMALE; GALLSTONE FORMATION; GENE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; INCIDENCE; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEX DIFFERENCE; SLCO1B1 GENE;

EID: 78650735648     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00736.x     Document Type: Article

References (47)

1. Hall MJ, Owings MF. 2000 National Hospital Discharge Survey. Advance data from vital and health statistics. No. 329. Hyattsville (MD): National Center for Health Statistics, 2002.
2. Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system. Gallstone disease. BMJ 2001; 13: 91-4.
3. Kang JY, Ellis C, Majeed A. Gallstones - an increasing problem: a study of hospital admission in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther 2003; 17: 561-9.
4. Khuroo MS, Mahajan R, Zargar SA, Javid G, Sapru S. Prevalence of biliary tract disease in India: a sonographic study in adult population in Kashmir. Gut 1989; 30: 201-5.
5. Choudhuri G, Agarwal DK, Negi TS. Polarizing microscopy of partially dissolved gallstone powder: a simple technique for studying gallstone composition. J Gastroenterol Hepatol 1995; 10: 241-5.
6. Tandon RK. Prevalence and type of biliary stones in India. World J Gastroenterol 2000; 6: 4-5.
7. Carey MC, Paigen B. Epidemiology of the American Indians' burden and its likely genetic origins. Hepatology 2002; 36: 781-91.
8. Wittenburg H, Lammert F. Genetic predisposition to gallbladder stones. Semin Liver Dis 2007; 27: 109-21.
9. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43, 141 twin pairs. Hepatology 2005; 41: 1138-43.
10. Nakeeb A, Comuzzie AG, Martin L et al. Gallstones: genetics versus environment. Ann Surg 2002; 235: 842-9.
11. Wang DQ, Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep 2004; 6: 140-50.
12. Portincasa P, Stolk MF, van Erpecum KJ, Palasciano G, van Berge-Henegouwen GP. Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Scand J Gastroenterol Suppl 1995; 212: 63-78.
13. Mendez-Sanchez N, Cardenas-Vazquez R, Ponciano-Rodriguez G, Uribe M. Pathophysiology of cholesterol gallstone disease. Arch Med Res 1996; 27: 433-41.
14. Portincasa P, Moschetta A, Calamita G, Margari A, Palasciano G. Pathobiology of cholesterol gallstone disease: from equilibrium ternary phase diagram to agents preventing cholesterol crystallization and stone formation. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 67-81.
15. Carey MC. Pathogenesis of gallstones. Am J Surg 1993; 165: 410-9.
16. Bertomeu A, Ros E, Zambón D et al. Apolipoprotein E polymorphism and gallstones. Gastroenterology 1996; 111: 1603-10.
17. Juvonen T, Savolainen MJ, Kairaluoma MI, Lajunen LH, Humphries SE, Kesäniemi YA. Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease. J Lipid Res 1995; 36: 804-12.
18. Kurzawski M, Juzyszyn Z, Modrzejewski A et al. Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease. Arch Med Res 2007; 38: 360-3.
19. Hofmann AF. The function of bile salts in fat absorption. The solvent properties of dilute micellar solutions of conjugated bile salts. Biochem J 1963; 89: 57-68.
20. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633-71.
21. St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 2001; 204: 1673-86.
22. Furihata T, Satoh T, Yamamoto N, Kobayashi K, Chiba K. Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm Res 2007; 24: 2327-32.
23. van der Deure WM, Friesema EC, de Jong FJ et al. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 2008; 149: 4695-701.
24. Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am J Physiol 1997; 272: G1285-303.
25. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007; 24: 239-47.
26. Yamaguchi H, Okada M, Akitaya S et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006; 47: 1196-202.
27. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 21: 35669-75.
28. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415-21.
29. Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-40.
30. Nishizato Y, Ieiri I, Suzuki H et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554-65.
31. Zhang W, He YJ, Gan Z et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol 2007; 34: 1240-4.
32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
33. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004; 56: 682-9.
34. Schneider S, Roessli D, Excoffier L. Arlequin: A Software for Population Genetics Data Analysis. User manual ver 2.0. Geneva: Genetics and Biometry Lab, Dept of Anthropology, University of Geneva, 2000.
35. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
36. Michalski C, Cui Y, Nies AT et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 8: 43058-63.
37. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003 (Jan); 10 (1609): 1-18.
38. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-42.
39. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513-22.
40. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
41. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008; 18: 921-6.
42. Ho WF, Koo SH, Yee JY, Lee EJ. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet 2008; 23: 476-82.
43. Tachibana-Iimori R, Tabara Y, Kusuhara H et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375-80.
44. Jindal C, Kumar S, Choudhari G, Goel H, Mittal B. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A > G) & susceptibility in gallstone disease. Indian J Med Res 2009; 129: 170-5.
45. Zhang W, Chen BL, Ozdemir V et al. SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007; 64: 346-52.
46. Chung JY, Cho JY, Yu KS et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005; 78: 342-50.
47. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-81.